This is a Phase 2, randomized, open-label controlled study to evaluate the efficacy and safety of Ampligen treatment compared to a control group / no treatment following FOLFIRINOX treatment in subjects with locally advanced pancreatic adenocarcinoma.
The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma